Oral erosive lichen planus treated with efalizumab.
Cheng
Amy
A
Department of Dermatology, Washington University, School of Medicine, St Louis, MO 63110, USA. amscheng@hotmail.com
Mann
Caroline
C
D000284:Administration, Oral; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007279:Injections, Subcutaneous; D017676:Lichen Planus, Oral / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018845:CD11 Antigens; D007166:Immunosuppressive Agents; D011241:Prednisone; D016559:Tacrolimus; C472181:efalizumab